Medtronic (MDT) is back in focus after William Blair upgraded the stock to Outperform, highlighting new product ramps tied to ...

Medtronic disclosed Diabetes unit executive pay packages for 2025 and compensation targets for when they'll lead MiniMed as a ...

Johnson & Johnson’s filing comes a month after Medtronic gained U.S. clearance for its Hugo system as competition in the soft ...

Wearable health devices may soon operate under looser regulatory oversight following new guidance from the FDA ...

The FDA-approved OmniaSecure defibrillation lead from Medtronic is a thin wire that connects an implantable cardioverter defibrillator to the heart.

These technologies are improving all the time. If they’re not making claims that they are medical grade, let’s let the market ...

Supermodel Bambi Northwood-Blyth wears a Dexcom glucose monitor. So does your next-door neighbor with type 2 diabetes and ...

Spinal cord stimulators can significantly improve patients’ lives. The province doesn’t fund nearly enough of them, experts ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson MedTech (NYSE: JNJ) announced today that it submitted its Ottava surgical robotic system to the FDA for de ...

Medtronic (MDT) is a strong defensive investment with stable growth, 49 years of dividend increases, and fair value. Read here for more analysis.

FDA issued a Class I recall for Medtronic's Left Heart Vent Catheters due to safety concerns. 3 injuries reported.